<DOC>
	<DOC>NCT02784366</DOC>
	<brief_summary>The purpose of this study is to establish a prospective observational cohort of cancer immunotherapy patients with GI side effects in order to identify biomarkers that predict GI complications due to treatment.</brief_summary>
	<brief_title>GI Complications in Cancer Immunotherapy Patients</brief_title>
	<detailed_description>Primary objective - To create a data and bio-specimen repository to enhance both safety and efficacy of immunotherapy Secondary objective - Identify biomarkers that may predict GI toxicity in cancer patients undergoing immunotherapy - Define the clinical course of intestinal inflammation and identify genetic factors of therapeutic response to GI medications - Analyze genotype-phenotype correlations in GI side effects in patients undergoing cancer immunotherapy</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Confirmed diagnosis of cancer Currently undergoing or have undergone immunotherapy History of a total colectomy History of inflammatory bowel disease (either ulcerative colitis or Crohn's disease) History of colitis on chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Cancer immunotherapy</keyword>
	<keyword>Ipilimumab</keyword>
</DOC>